As microbial-based biologics and antibody-drug conjugates (ADCs) continue to gain traction across the therapeutic landscape, development and manufacturing success increasingly rely on specialized expertise, integrated technologies, and coordinated operational models. Whether advancing microbial expression systems or highly potent conjugated therapies, sponsors face distinct challenges related to strain development, fermentation scale-up, conjugation, containment, quality assurance, regulatory alignment, and commercialization readiness.
This edition of the Outsourced Pharma Capabilities Update (OPCU) highlights the capabilities CDMOs bring to microbial manufacturing and ADC development, showcasing expertise across strain engineering, upstream and downstream processing, high-potency handling, analytical characterization, and integrated development frameworks. Join us to explore the technical platforms, collaborative strategies, and manufacturing approaches that help sponsors reduce risk, maintain process continuity, and accelerate complex biologics from early development through clinical and commercial production.
Recent Sessions Available On-Demand
Large Molecule and Combination Products & Drug Delivery – May 2026
Fill/Finish and Small Molecule Drug Product – May 2026
Upcoming OPCU Topics & Times
Gene Therapy | 7/28/2026, AM Session
Fill/Finish | 7/29/2026, AM Session
Large Molecule | 7/29/2026, PM Session
Cell Line Development | 8/5/2026, AM Session
Access more on-demand OPCU recordings and upcoming sessions here.
